Merger Deal Updates, Dividend, Dispute Settlement, Regulatory Application Submission, and Preliminary Results - Research Reports on Shire, Johnson & Johnson, Merck, Amgen and HCA

NEW YORK, October 21, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Shire plc (NASDAQ: SHPG), Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Amgen Inc. (NASDAQ: AMGN) and HCA Holdings, Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7333-100free.

--
Shire plc Research Reports
On October 15, 2014, Shire plc (Shire) reported that it has received a notice from AbbVie Inc. (AbbVie) in which the latter has informed about its intentions to reconsider its recommendation of the offer for Shire, in light of the impact of the US Treasury Notice of September 22, 2014. Shire's Board also notified that in the event of adverse changes in AbbVie's recommendation and non-receipt of approval from AbbVie's shareholders, the Company will be entitled to receive a break-up fee of c.$1.6 billion from AbbVie. As per a Reuters report dated On October 16, 2014, AbbVie informed that the changes in the U.S. tax regime "eliminated certain of the financial benefits of the transaction, most notably the ability to access current and future global cash flows in a tax efficient manner as originally contemplated in the transaction. This fundamentally changed the implied value of Shire to AbbVie in a significant manner." The full research reports on Shire are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/SHPG/report.pdf

--
Johnson & Johnson Research Reports
On October 16, 2014, Johnson & Johnson announced that its Board of Directors has declared a cash dividend for Q4 2014 of $0.70 per share on the Company's common stock. The dividend is payable on December 9, 2014 to shareholders of record at the close of business on November 25, 2014. The full research reports on Johnson & Johnson are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/JNJ/report.pdf

--
Merck & Co. Inc. Research Reports
On October 16, 2014, Reuters reported that Merck & Co. Inc.'s subsidiary Organon USA Inc. (Organon) has agreed to pay $31 million to the U.S. states to settle disputes over overcharging for its Remeron antidepressant drug. According to the report, Organon charged the full cost of Remeron from the state Medicaid programs, while it sold the same drug at a discount to the pharmacy companies. Reuters reported that the settlement agreement involves state of Washington, D.C., and every state besides Arizona. As per the report, Organon was also accused of improperly promoting use of the drug by children and teens. The full research reports on Merck are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/MRK/report.pdf

--
Amgen Inc. Research Reports
On October 9, 2014, Amgen Inc. (Amgen) announced that its Biologics License Application (BLA) seeking approval for the investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab, has been accepted for a priority review by the U.S. Food and Drug Administration (FDA). Amgen informed that it has sought the FDA's approval for blinatumomab for the treatment of adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow. In addition, the Company said that it has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for the approval to market blinatumomab. According to the Company, in the U.S., over 6,000 cases of ALL will be diagnosed in 2014, and in the European Union, it is estimated that more than 7,000 cases of ALL are diagnosed each year. The full research reports on Amgen are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/AMGN/report.pdf

--
HCA Holdings, Inc. Research Reports
On October 15, 2014, HCA Holdings, Inc. (HCA) announced preliminary financial and operating results for Q3 2014. The Company expects Q3 2014 revenues to be approx. $9.2 billion, compared to $8.5 billion in the year ago period. Net income for the quarter is expected to be approximately $1.16 per diluted share, compared to $0.79 for Q3 2013. HCA informed that the Q3 2014 results will include losses of $0.02 per diluted share on account of sales of facilities. Analysts surveyed by Bloomberg Businessweek expect HCA's Q3 2014 net income at $0.96 per share on revenue of $9.0 billion. For full-year 2014, HCA now expects adjusted diluted EPS to be in the range of $4.40 - $4.60, compared to the range of $4.00 - $4.25 forecasted earlier. Also, revenues for full-year 2014 are now seen in the range of $36.50 - $37.00 billion versus the range of $36.00 - $36.50 billion forecasted previously. Shares of the Company rose 5.23% on October 16, 2014 to close at $68.23. The full research reports on HCA are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/HCA/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED